Session

COVID-19 complications in the lower GI tract

REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY INRESPONSEIN IBDAGAINSTSARS-COV-2IMMUNISATION)
REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY INRESPONSEIN IBDAGAINSTSARS-COV-2IMMUNISATION)

POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY
POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY

INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH AN INCREASED RISK FOR COVID-19-RELATED HOSPITALIZATION, BUT NOT WITH MORTALITY: CROATIAN NATIONWIDE COHORT STUDY
INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH AN INCREASED RISK FOR COVID-19-RELATED HOSPITALIZATION, BUT NOT WITH MORTALITY: CROATIAN NATIONWIDE COHORT STUDY

POST-COVID GASTROINTESTINAL SEQUELAE 7 MONTHS AFTER ACUTE SARS-COV-2 INFECTION
POST-COVID GASTROINTESTINAL SEQUELAE 7 MONTHS AFTER ACUTE SARS-COV-2 INFECTION

SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS
SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS

SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS
SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS

COVID-19 complications in the lower GI tract  et al.

POST-COVID GASTROINTESTINAL SEQUELAE 7 MONTHS AFTER ACUTE SARS-COV-2 INFECTION
POST-COVID GASTROINTESTINAL SEQUELAE 7 MONTHS AFTER ACUTE SARS-COV-2 INFECTION

COVID-19 complications in the lower GI tract  et al.

INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH AN INCREASED RISK FOR COVID-19-RELATED HOSPITALIZATION, BUT NOT WITH MORTALITY: CROATIAN NATIONWIDE COHORT STUDY
INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH AN INCREASED RISK FOR COVID-19-RELATED HOSPITALIZATION, BUT NOT WITH MORTALITY: CROATIAN NATIONWIDE COHORT STUDY

COVID-19 complications in the lower GI tract  et al.

POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY
POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY

COVID-19 complications in the lower GI tract  et al.

REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY INRESPONSEIN IBDAGAINSTSARS-COV-2IMMUNISATION)
REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY INRESPONSEIN IBDAGAINSTSARS-COV-2IMMUNISATION)

COVID-19 complications in the lower GI tract  et al.

Item 1 - 10 / 10
1